• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug-induced changes of extracerebral dopa metabolism in man.

作者信息

Tissot R, Bartholini G, Pletscher A

出版信息

Arch Neurol. 1969 Feb;20(2):187-90. doi: 10.1001/archneur.1969.00480080087010.

DOI:10.1001/archneur.1969.00480080087010
PMID:5767016
Abstract
摘要

相似文献

1
Drug-induced changes of extracerebral dopa metabolism in man.
Arch Neurol. 1969 Feb;20(2):187-90. doi: 10.1001/archneur.1969.00480080087010.
2
[Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
Clin Chim Acta. 1971 Jun;33(1):111-5. doi: 10.1016/0009-8981(71)90257-9.
3
The metabolism of L-3-O-methyldopa, a precursor of dopa in man.
Clin Pharmacol Ther. 1971 Jul-Aug;12(4):678-82. doi: 10.1002/cpt1971124678.
4
Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation.通过抑制脑外左旋多巴脱羧作用选择性提高脑内多巴胺水平。
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):344-52. doi: 10.1002/cpt1971122part2344.
5
Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.
Biochem Pharmacol. 1972 Aug 1;21(15):2144-7. doi: 10.1016/0006-2952(72)90169-4.
6
Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.帕金森病中的外周芳香族L-氨基酸脱羧酶抑制剂。II. 对L-2-¹⁴C-多巴代谢的影响
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):584-94. doi: 10.1002/cpt1972134584.
7
[Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
Rev Eur Etud Clin Biol. 1972 Jan;17(1):38-44.
8
Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.大鼠口服（14C）-O-甲基多巴和（14C）-L-多巴后的吸收、代谢及分布
Br J Pharmacol. 1974 Feb;50(2):259-63. doi: 10.1111/j.1476-5381.1974.tb08570.x.
9
3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
Clin Chim Acta. 1972 Mar;37:359-69. doi: 10.1016/0009-8981(72)90456-1.
10
Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.l-[14C]多巴在人体脑脊液和血浆中的代谢命运。
Brain Res. 1967 Feb;4(1):106-9. doi: 10.1016/0006-8993(67)90154-0.

引用本文的文献

1
Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.胱硫醚-β-合酶：分子调控与药物抑制。
Biomolecules. 2020 Apr 30;10(5):697. doi: 10.3390/biom10050697.
2
Pharmacokinetic optimisation in the treatment of Parkinson's disease.帕金森病治疗中的药代动力学优化
Clin Pharmacokinet. 1996 Jun;30(6):463-81. doi: 10.2165/00003088-199630060-00004.
3
Distribution and metabolism of L-3-O-methyldopa in rats.L-3-O-甲基多巴在大鼠体内的分布与代谢
Br J Pharmacol. 1970 Nov;40(3):461-7. doi: 10.1111/j.1476-5381.1970.tb10627.x.
4
Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.左旋多巴联合外周脱羧酶抑制用于帕金森病治疗
Can Med Assoc J. 1972 Jun 10;106(11):1169-74.
5
L-dopa level in plasma, primary condition for the kinetic effect.血浆中左旋多巴水平，这是动力学效应的首要条件。
J Neural Transm. 1973;34(2):133-43. doi: 10.1007/BF01244666.
6
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.左旋多巴：对其药理特性及治疗用途的综述，特别提及帕金森病
Drugs. 1971;2(4):262-400. doi: 10.2165/00003495-197102040-00002.
7
Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.
Naunyn Schmiedebergs Arch Pharmacol. 1973;280(4):429-39. doi: 10.1007/BF00506633.
8
Decarboxylation of orally administered L-dopa in the human digestive tract.
Naunyn Schmiedebergs Arch Pharmacol. 1972;272(4):437-40. doi: 10.1007/BF00501249.
9
Changes in taste under L-DOPA therapy.
Z Neurol. 1971;200(4):345-8. doi: 10.1007/BF00316598.
10
Clinical pharmacokinetics of anti-parkinsonian drugs.抗帕金森病药物的临床药代动力学
Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.